Tate's most recent trade in Huntington Bancshares, Inc. was a trade of 503 Common Stock done . Disclosure was reported to the exchange on April 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2026 | 503 | 113,614 (0%) | 0% | 0 | Common Stock | |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2026 | 49 | 5,158 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | EVP - Chief Peop/Strat Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2026 | 2,779 | 32,784 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | EVP - Chief Peop/Strat Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 11 Mar 2026 | 1,011 | 31,773 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | EVP - Chief Peop/Strat Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 2,440 | 30,005 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | EVP - Chief Peop/Strat Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 Mar 2026 | 335 | 27,565 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | EVP - Chief Peop/Strat Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2026 | 3,444 | 27,900 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | EVP - Chief Peop/Strat Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 25 Feb 2026 | 425 | 24,456 (0%) | 0% | 0 | Common Stock | |
| Trustmark Corp | Granville Tate | Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2026 | 3,393 | 61,351 (0%) | 0% | 0 | Common Stock | |
| Trustmark Corp | Granville Tate | Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 6,841 | 59,898 (0%) | 0% | 0 | Common Stock | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 122.84 per share. | 17 Feb 2026 | 4,250 | 199,081 | - | 122.8 | 522,086 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 123.93 per share. | 17 Feb 2026 | 3,556 | 195,525 | - | 123.9 | 440,690 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 124.66 per share. | 17 Feb 2026 | 2,281 | 193,244 | - | 124.7 | 284,343 | Common Stock |
| Trustmark Corp | Granville Tate | Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.82 per share. | 17 Feb 2026 | 1,940 | 57,958 (0%) | 0% | 44.8 | 86,951 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 126.34 per share. | 17 Feb 2026 | 1,161 | 192,083 | - | 126.3 | 146,681 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 122.16 per share. | 17 Feb 2026 | 753 | 203,331 | - | 122.2 | 91,984 | Common Stock |
| Trustmark Corp | Granville Tate | Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.73 per share. | 13 Feb 2026 | 1,326 | 53,057 (0%) | 0% | 44.7 | 59,312 | Common Stock |
| Dow | Jeffrey L. Tate | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 115,350 | 115,350 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Dow | Jeffrey L. Tate | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 21,200 | 118,761 (0%) | 0% | 0 | Common Stock | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2026 | 11,787 | 204,084 | - | 0 | Common Stock | |
| Belden Inc | Leah Tate | SVP - HR | Sale of securities on an exchange or to another person at price $ 130.00 per share. | 04 Feb 2026 | 2,954 | 24,881 (0%) | 0% | 130 | 384,020 | Common Stock |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 453 | 113,110 (0%) | 0% | 0 | Common Stock | |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 45 | 5,109 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | SVP - HR | Sale of securities on an exchange or to another person at price $ 120.00 per share. | 03 Dec 2025 | 2,554 | 27,835 (0%) | 0% | 120 | 306,480 | Common Stock |
| Healthstream Inc | Deborah Tate | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Dec 2025 | 394 | 21,551 (0%) | 0% | 0 | Common Stock Holding | |
| Healthstream Inc | Deborah Tate | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Dec 2025 | 40 | 21,945 (0%) | 0% | 0 | Common Stock Holding | |
| Healthstream Inc | Deborah Tate | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Nov 2025 | 1,142 | 21,985 (0%) | 0% | 0 | Common Stock Holding | |
| Dow | Jeffrey L. Tate | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 23.85 per share. | 28 Nov 2025 | 524 | 97,561 (0%) | 0% | 23.8 | 12,497 | Common Stock |
| Healthstream Inc | Deborah Tate | Director | Sale of securities on an exchange or to another person at price $ 25.46 per share. | 26 Nov 2025 | 1,580 | 23,127 (0%) | 0% | 25.5 | 40,227 | Common Stock Holding |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 144.53 per share. | 17 Nov 2025 | 4,459 | 195,535 | - | 144.5 | 644,478 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 143.52 per share. | 17 Nov 2025 | 3,238 | 192,297 | - | 143.5 | 464,703 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 145.69 per share. | 17 Nov 2025 | 2,609 | 199,994 | - | 145.7 | 380,107 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 146.42 per share. | 17 Nov 2025 | 1,124 | 202,603 | - | 146.4 | 164,571 | Common Stock |
| Aviat Networks Inc | Bruce M. Taten | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2025 | 5,480 | 23,659 (0%) | 0% | 0 | Common Stock | |
| Aviat Networks Inc | Bruce M. Taten | Director | Sale of securities on an exchange or to another person at price $ 23.39 per share. | 07 Nov 2025 | 3,268 | 20,391 (0%) | 0% | 23.4 | 76,439 | Common Stock |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 461 | 112,657 (0%) | 0% | 0 | Common Stock | |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 45 | 5,063 (0%) | 0% | 0 | Common Stock | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Sep 2025 | 7,000 | 450,281 | - | 0 | Common Stock | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Aug 2025 | 55,785 | 203,727 | - | 0 | Common Stock | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Aug 2025 | 55,785 | 457,281 | - | 0 | Common Stock | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 183.83 per share. | 18 Aug 2025 | 9,668 | 268,705 | - | 183.8 | 1,777,310 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 183.17 per share. | 18 Aug 2025 | 9,193 | 259,512 | - | 183.2 | 1,683,874 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 190.82 per share. | 12 Aug 2025 | 66,561 | 434,935 | - | 190.8 | 12,700,864 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 191.92 per share. | 12 Aug 2025 | 32,374 | 402,561 | - | 191.9 | 6,213,095 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 192.52 per share. | 12 Aug 2025 | 1,065 | 401,496 | - | 192.5 | 205,029 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 169.61 per share. | 07 Aug 2025 | 43,184 | 575,812 | - | 169.6 | 7,324,352 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 169.61 per share. | 07 Aug 2025 | 43,184 | 575,812 | - | 169.6 | 7,324,352 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 173.82 per share. | 07 Aug 2025 | 34,125 | 518,996 | - | 173.8 | 5,931,724 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 173.82 per share. | 07 Aug 2025 | 34,125 | 518,996 | - | 173.8 | 5,931,724 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 171.48 per share. | 07 Aug 2025 | 15,141 | 553,121 | - | 171.5 | 2,596,345 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 171.48 per share. | 07 Aug 2025 | 15,141 | 553,121 | - | 171.5 | 2,596,345 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Aug 2025 | 10,000 | 501,496 | - | 0 | Common Stock | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Aug 2025 | 10,000 | 501,496 | - | 0 | Common Stock | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 170.34 per share. | 07 Aug 2025 | 7,550 | 568,262 | - | 170.3 | 1,286,064 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 170.34 per share. | 07 Aug 2025 | 7,550 | 568,262 | - | 170.3 | 1,286,064 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Aug 2025 | 7,500 | 7,500 | - | 0 | Common Stock | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Aug 2025 | 7,500 | 511,496 | - | 0 | Common Stock | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Aug 2025 | 7,500 | 511,496 | - | 0 | Common Stock | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2025 | 43,238 | 278,373 | - | 0 | Common Stock | |
| Belden Inc | Leah Tate | SVP - HR | Other type of transaction at price $ 96.62 per share. | 10 Jul 2025 | 219 | 30,389 (0%) | 0% | 96.6 | 21,160 | Common Stock |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 453 | 112,196 (0%) | 0% | 0 | Common Stock | |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 45 | 5,018 (0%) | 0% | 0 | Common Stock | |
| Healthstream Inc | Deborah Tate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 2,132 | 24,707 (0%) | 0% | 0 | Common Stock Holding | |
| Healthstream Inc | Deborah Tate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 1,126 | 1,126 | - | - | Restricted Share Units | |
| Healthstream Inc | Deborah Tate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 1,006 | 2,012 | - | - | Restricted Share Units | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 90.75 per share. | 30 May 2025 | 204,954 | 645,556 | - | 90.8 | 18,599,760 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 90.06 per share. | 30 May 2025 | 156,288 | 850,510 | - | 90.1 | 14,076,047 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 89.05 per share. | 30 May 2025 | 92,200 | 1,006,798 | - | 89.0 | 8,210,272 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 88.14 per share. | 30 May 2025 | 19,998 | 1,098,998 | - | 88.1 | 1,762,708 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 92.04 per share. | 30 May 2025 | 15,492 | 630,064 | - | 92.0 | 1,425,831 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 94.33 per share. | 30 May 2025 | 7,100 | 618,996 | - | 94.3 | 669,729 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 92.96 per share. | 30 May 2025 | 3,968 | 626,096 | - | 93.0 | 368,861 | Common Stock |
| Healthstream Inc | Deborah Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 3,048 | 3,048 | - | - | Restricted Share Units | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 90.67 per share. | 16 May 2025 | 4,247 | 239,114 | - | 90.7 | 385,087 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 90.33 per share. | 16 May 2025 | 3,979 | 235,135 | - | 90.3 | 359,440 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 92.16 per share. | 16 May 2025 | 881 | 243,361 | - | 92.2 | 81,189 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 85.77 per share. | 13 May 2025 | 1,667 | 31,837 (0%) | 0% | 85.8 | 142,979 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 1,667 | 1,666 | - | - | Stock Appreciation Rights | |
| Belden Inc | Leah Tate | SVP - HR | Sale or transfer of securities back to the company at price $ 113.85 per share. | 13 May 2025 | 1,436 | 30,401 (0%) | 0% | 113.9 | 163,489 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Sale of securities on an exchange or to another person at price $ 113.64 per share. | 13 May 2025 | 231 | 30,170 (0%) | 0% | 113.6 | 26,251 | Common Stock |
| JELD-WEN Holding Inc | Bruce M. Taten | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 37,974 | 107,641 (0%) | 0% | 0 | Common Stock | |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 9,404 | 111,742 (0%) | 0% | 0 | Common Stock | |
| JELD-WEN Holding Inc | Bruce M. Taten | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.34 per share. | 25 Apr 2025 | 3,576 | 69,667 (0%) | 0% | 5.3 | 19,096 | Common Stock |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 419 | 102,338 (0%) | 0% | 0 | Common Stock | |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 51 | 4,972 (0%) | 0% | 0 | Common Stock | |
| Healthstream Inc | Deborah Tate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 1,149 | 22,575 (0%) | 0% | 0 | Common Stock Holding | |
| Healthstream Inc | Deborah Tate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 1,149 | 0 | - | - | Restricted Share Units | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Feb 2025 | 125,800 | 1,118,996 | - | 0 | Common Stock | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 82.53 per share. | 26 Feb 2025 | 125,800 | 0 | - | 82.5 | 10,382,890 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Feb 2025 | 125,800 | 125,800 | - | 0 | Common Stock | |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Feb 2025 | 125,800 | 1,244,796 | - | 0 | Common Stock | |
| Belden Inc | Leah Tate | SVP - HR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 4,518 | 27,085 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | SVP - HR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 3,085 | 30,170 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 441 | 0 | - | - | Stock Appreciation Rights | |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.79 per share. | 21 Feb 2025 | 441 | 23,008 (0%) | 0% | 53.8 | 23,721 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2025 | 435 | 22,808 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | SVP - HR | Sale or transfer of securities back to the company at price $ 111.09 per share. | 21 Feb 2025 | 277 | 22,731 (0%) | 0% | 111.1 | 30,772 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2025 | 241 | 22,567 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | SVP - HR | Sale of securities on an exchange or to another person at price $ 111.76 per share. | 21 Feb 2025 | 164 | 22,567 (0%) | 0% | 111.8 | 18,329 | Common Stock |
| Astera Labs Inc | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 92.07 per share. | 18 Feb 2025 | 34,474 | 244,242 | - | 92.1 | 3,174,028 | Common Stock |
| Trustmark Corp | Granville Tate | Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.67 per share. | 14 Feb 2025 | 1,100 | 54,383 (0%) | 0% | 37.7 | 41,437 | Common Stock |